Loading…
Loading…
Anti-TNF, IL-6, CTLA-4, B-cell, and JAK inhibitor stratification and safety
Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have transformed the management of inflammatory rheumatic diseases, enabling remission in conditions previously refractory to conventional therapy. At Dr. Shree Narayan's clinic, biologic selection is guided by disease phenotype, serological status, comorbidity profile, patient preference, and evidence from randomised controlled trials. Pre-treatment screening encompasses infection risk assessment (TB, hepatitis B/C, HIV), vaccination status, cardiovascular risk stratification (particularly for JAK inhibitors), and malignancy history. Therapeutic drug monitoring (TDM) using trough levels and anti-drug antibodies is employed to differentiate primary non-response from immunogenic secondary loss of response.
Kathmandu Neurology Clinic & Cognitive Center
Authored and reviewed by Dr. Shree Narayan Yadav (MBBS (KU), MD-Internal Medicine (NAMS), MSc Clinical Rheumatology (USW, UK), NMC 14227). Evidence-based, no fabricated outcomes.
Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have transformed the management of inflammatory rheumatic diseases, enabling remission in conditions previously refractory to conventional therapy. At Dr. Shree Narayan's clinic, biologic selection is guided by disease phenotype, serological status, comorbidity profile, patient preference, and evidence from randomised controlled trials. Pre-treatment screening encompasses infection risk assessment (TB, hepatitis B/C, HIV), vaccination status, cardiovascular risk stratification (particularly for JAK inhibitors), and malignancy history. Therapeutic drug monitoring (TDM) using trough levels and anti-drug antibodies is employed to differentiate primary non-response from immunogenic secondary loss of response.
Reviewed by Dr. Shree Narayan Yadav, MBBS, MD, MSc — Consultant Physician & Joint and Autoimmune Disease Specialist (NMC 14227), Kathmandu Neurology Clinic. For evaluation, book an appointment.
Current bDMARDs target distinct nodes of the inflammatory cascade. Anti-TNF agents (adalimumab, etanercept, infliximab, golimumab, certolizumab) neutralise tumour necrosis factor-alpha, a key cytokine in RA, spondyloarthropathy, and IBD-associated arthritis. IL-6 inhibitors (tocilizumab, sarilumab) block interleukin-6 signalling and are particularly effective in systemic JIA, GCA, and RA with high inflammatory burden. CTLA-4-Ig (abatacept) blocks T-cell co-stimulation and is effective in RA (especially anti-CCP positive). Anti-CD20 (rituximab) depletes B-cells and is preferred for ANCA-associated vasculitis and RA with autoantibody-positive disease. IL-17 inhibitors (secukinumab, ixekizumab) target the IL-17A axis and are first-line biologics in psoriatic arthritis and axial SpA.
Guidelines referenced:
Before initiating any biologic or JAK inhibitor, comprehensive screening is mandatory. Tuberculosis screening requires either tuberculin skin test (TST) or interferon-gamma release assay (IGRA), plus chest X-ray. Active TB must be excluded and latent TB treated with isoniazid for at least 4 weeks before biologic initiation. Hepatitis B surface antigen, hepatitis B core antibody, and hepatitis C antibody must be checked; HBsAg-positive patients require antiviral prophylaxis with entecavir or tenofovir during biologic therapy. Varicella zoster immunity should be confirmed and vaccination offered if seronegative. COVID-19 vaccination and boosters should be completed before or during biologic therapy.
Approximately 30-40% of RA patients fail to achieve adequate response to their first biologic (primary non-response), and a further 20-40% lose response over time (secondary loss of response). Therapeutic drug monitoring (TDM) measuring trough drug levels and anti-drug antibody (ADA) levels helps guide management: adequate trough with no response suggests mechanism failure (switch within or across class), while low trough with ADA suggests immunogenic loss of response (switch within class or add methotrexate). TDM-guided dose optimisation can improve outcomes and reduce healthcare costs compared with clinical response-based switching alone.
Smolen JS et al. EULAR recommendations for bDMARD and tsDMARD management in RA: 2022 update. Ann Rheum DisLandewe RBM et al. EULAR recommendations for pre-treatment screening before biologic therapy. Ann Rheum Dis 2023Ytterberg SR et al. Cardiovascular and cancer risk with tofacitinib in RA (ORAL Surveillance). N Engl J MedContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.